Petrina Kamya, PhD, is the Head of AI Platforms at Insilico Medicine, an end-to-end artificial intelligence-driven drug discovery company. Prior to joining Insilico, Dr. Kamya led sales and business development of molecular modeling software for pharma and biotech companies at Chemical Computing Group and served as a Market Access Manager for Cetara. During the COVID-19 pandemic, Dr. Kamya provided due diligence around AI tools for investment banks and was introduced to Insilico Medicine and its AI drug discovery platform, Pharma.AI, which includes novel target discovery (PandaOmics), novel small molecule design (Chemistry42) and clinical trial prediction (InClinico). She saw the potential of Insilico’s platform to optimize drug design with speed and efficiency and to meaningfully improve the drug discovery process. She joined the team in August 2020, initially leading its Chemistry42 platform. She holds a PhD in Chemistry from Concordia University.